C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 213/75 (2006.01) A61K 31/44 (2006.01) A61P 25/22 (2006.01) A61P 25/24 (2006.01)
Patent
CA 2602445
The present invention relates to compounds of the general formula (I) wherein R is methyl; and R1 is 4-methyl-4-oxy-piperazin-l-yl; or R is CH2OH and R1 is 4-methyl-piperazin-l-yl or is 4-methyl-4-oxy-piperazin-l-yl; and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-I receptor related diseases.
La présente invention concerne des composés de formule générale (I) dans laquelle R est un groupe méthyle; et R1 est un groupe 4-méthyl-4-oxy-pipérazin-l-yl; ou R est un groupe CH2OH et R1 est un groupe 4-méthyl-pipérazin-l-yl ou un groupe 4-méthyl-4-oxy-pipérazin-l-yl; et leurs sels d~addition d~acide pharmaceutiquement acceptables pour le traitement des maladies associées au récepteur NK-I.
Funk Christoph
Hoffmann Torsten
Koblet Andreas
Borden Ladner Gervais Llp
F.hoffmann-La Roche Ag
LandOfFree
Metabolites for nk-i antagonists for emesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabolites for nk-i antagonists for emesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabolites for nk-i antagonists for emesis will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2019208